Cover Image
市場調查報告書

Eli Lilly and Company的產品平台分析

Eli Lilly and Company - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 240920
出版日期 內容資訊 英文 242 Pages
訂單完成後即時交付
價格
Back to Top
Eli Lilly and Company的產品平台分析 Eli Lilly and Company - Product Pipeline Review - 2016
出版日期: 2016年02月29日 內容資訊: 英文 242 Pages
簡介

Eli Lilly and Company是以美國為據點的製藥企業,從事醫藥品的研究、開發、製造及銷售。該公司的產品系列中包括有神經科學、內分泌系、腫瘤、心血管、動物醫療等各種產品。

本報告提供Eli Lilly and Company的治療藥開發平台現狀與各開發階段的比較分析,藥物標的,作用機制,給藥途徑,各分子類型治療藥的評估,最新的企業新聞和發表,後期階段及中止的計劃相關資訊等。

Eli Lilly and Company的基本資料

Eli Lilly and Company概要

  • 主要資訊
  • 企業資料

Eli Lilly and Company:R&D概要

  • 主要的治療範圍

Eli Lilly and Company:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
  • 轉出授權產品

Eli Lilly and Company:開發中產品概況

  • 最後階段的開發中產品
  • 臨床實驗階段的開發中產品
  • 初期階段產品開發中產品

Eli Lilly and Company:藥物簡介

  • cetuximab
  • dulaglutide
  • insulin glargine
  • ramucirumab
  • tadalafil
  • vancomycin
  • baricitinib
  • duloxetine hydrochloride DR
  • evacetrapib
  • insulin peglispro
  • ixekizumab
  • LY-2835219
  • necitumumab
  • solanezumab
  • tabalumab
  • teriparatide
  • edivoxetine
  • galunisertib
  • blosozumab
  • emibetuzumab
  • erteberel
  • gandotinib
  • icrucumab
  • LY-2090314
  • LY-2409021
  • LY-2495655
  • LY-2510924
  • LY-2606368
  • LY-2801653
  • LY-2928057
  • LY-2940094
  • LY-2944876
  • LY-2951742
  • LY-3015014
  • LY-3016859
  • olaratumab
  • pemetrexed disodium
  • ralimetinib mesylate
  • taladegib
  • LY-3053102
  • IMC-3C5
  • IMC-CS4
  • LY-2780301
  • LY-2787106
  • LY-2874455
  • LY-2922083
  • LY-2922470
  • LY-2969822
  • LY-2979165
  • LY-3002813
  • LY-3006072
  • LY-3009120
  • LY-3022859
  • LY-3023414
  • LY-3025876
  • LY-3039478
  • LY-3045697
  • LY-3050258
  • LY-3074828
  • LY-3084077
  • LY-3090106
  • LY-3108743
  • LY-3127760
  • LY-404039
  • TT-401
  • cercosporamide
  • CPZEN-45
  • LLY-2707
  • LSN-2463359
  • LSN-2535717
  • LSN-2814617
  • LY-2109761
  • LY-2607540
  • LY-2857785
  • LY-364937
  • LYTAK-1
  • 癌症治療用單株抗體
  • ND-09759
  • Peptide For Type 2 Diabetes And Obesity
  • Bispecific Monoclonal Antibodies For Oncology
  • Polycyclic Guanidine Derivative for Type 2 Diabetes
  • Small Molecules to Inhibit Beta Secretase for Alzheimer's Disease

Eli Lilly and Company:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Eli Lilly and Company:最近的開發平台趨勢

Eli Lilly and Company:暫停中的計劃

Eli Lilly and Company:開發中止的開發中產品

  • 開發中止的開發中產品簡介

Eli Lilly and Company:企業發表

Eli Lilly and Company:總公司和子公司的所在地

Eli Lilly and Company:主要製造設備

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07969CDB

Summary

Global Markets Direct's, 'Eli Lilly and Company - Product Pipeline Review - 2016', provides an overview of the Eli Lilly and Company's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Eli Lilly and Company, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Eli Lilly and Company
  • The report provides overview of Eli Lilly and Company including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Eli Lilly and Company's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Eli Lilly and Company's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Eli Lilly and Company's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Eli Lilly and Company
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Eli Lilly and Company's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Eli Lilly and Company Snapshot
    • Eli Lilly and Company Overview
    • Key Information
    • Key Facts
  • Eli Lilly and Company - Research and Development Overview
    • Key Therapeutic Areas
  • Eli Lilly and Company - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
    • Pipeline Products - Out-Licensed Products
  • Eli Lilly and Company - Pipeline Products Glance
  • Eli Lilly and Company - Late Stage Pipeline Products
  • Eli Lilly and Company - Clinical Stage Pipeline Products
  • Eli Lilly and Company - Early Stage Pipeline Products
  • Eli Lilly and Company - Drug Profiles
    • baricitinib
    • duloxetine hydrochloride DR
    • ixekizumab
    • necitumumab
    • olaratumab
    • ramucirumab
    • cetuximab
    • abemaciclib
    • AMG-5041
    • insulin peglispro
    • LY-2951742
    • odelepran hydrochloride
    • solanezumab
    • tadalafil
    • galunisertib
    • blosozumab
    • edivoxetine hydrochloride
    • emibetuzumab
    • erteberel
    • icrucumab
    • insulin lispro U100
    • landogrozumab
    • LY-2510924
    • LY-2623091
    • LY-2874455
    • LY-2928057
    • LY-2944876
    • LY-3015014
    • LY-3016859
    • LY-3023414
    • LY-3074828
    • merestinib
    • prexasertib
    • ralimetinib mesylate
    • LY-2780301
    • LY-3039478
    • Biologic 6 for Diabetes
    • Biologic for Crohn's Disease
    • Biologic for Diabetic Nephropathy
    • Biologic for Hypoglycemia
    • Biologic for Lupus
    • Biologic for Neutrophilic Dermatosis
    • Biologic for Renal Anemia
    • dulaglutide
    • insulin lispro U200
    • LY-2599666
    • LY-2969822
    • LY-3002813
    • LY-3009120
    • LY-3022855
    • LY-3025876
    • LY-3041658
    • LY-3050258
    • LY-3076226
    • LY-3079514
    • LY-3090106
    • LY-3108743
    • LY-3114062
    • LY-3127760
    • LY-3127804
    • LY-3143753
    • LY-3154207
    • LY-3164530
    • LY-3185643
    • LY-3200327
    • LY-3202626
    • LY-3337641
    • LY-900014
    • Recombinant Protein for Parkinson's Disease
    • Small Molecule 4 for Diabetes
    • cercosporamide
    • CPZEN-45
    • LLY-2707
    • LSN-2463359
    • LSN-2535717
    • LSN-2814617
    • LY-2109761
    • LY-2607540
    • LY-2811376 + LY-3002813
    • LY-2857785
    • LY-344545
    • Monoclonal Antibody Conjugate 2 for Oncology
    • Monoclonal Antibody Conjugate 3 for Oncology
    • Monoclonal Antibody to Antagonize IGF-IR and Inhibit VEGF for Oncology
    • ND-09759
    • Small Molecule to Agonize TR-Beta for Dyslipidemia
    • Small Molecule to Antagonize mGlu5 for Pain
    • Drugs for Oncology
    • IC-87201
    • Monoclonal Antibodies for Undisclosed Indication
    • Small Molecule for Type 2 Diabetes
    • Small Molecule to Antagonize EP4 Receptor for Pain and Inflammation
    • Small Molecule to Inhibit MPGES-1 for Inflammation and Pain
  • Eli Lilly and Company - Pipeline Analysis
    • Eli Lilly and Company - Pipeline Products by Target
    • Eli Lilly and Company - Pipeline Products by Route of Administration
    • Eli Lilly and Company - Pipeline Products by Molecule Type
    • Eli Lilly and Company - Pipeline Products by Mechanism of Action
  • Eli Lilly and Company - Recent Pipeline Updates
  • Eli Lilly and Company - Dormant Projects
  • Eli Lilly and Company - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
  • Eli Lilly and Company - Company Statement
  • Eli Lilly and Company - Locations and Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Eli Lilly and Company - Key Manufacturing Facilities
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Eli Lilly and Company, Key Information
  • Eli Lilly and Company, Key Facts
  • Eli Lilly and Company - Pipeline by Indication, 2016
  • Eli Lilly and Company - Pipeline by Stage of Development, 2016
  • Eli Lilly and Company - Monotherapy Products in Pipeline, 2016
  • Eli Lilly and Company - Combination Treatment Modalities in Pipeline, 2016
  • Eli Lilly and Company - Partnered Products in Pipeline, 2016
  • Eli Lilly and Company - Partnered Products/ Combination Treatment Modalities, 2016
  • Eli Lilly and Company - Out-Licensed Products in Pipeline, 2016
  • Eli Lilly and Company - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Eli Lilly and Company - Pre-Registration, 2016
  • Eli Lilly and Company - Filing rejected/Withdrawn, 2016
  • Eli Lilly and Company - Phase III, 2016
  • Eli Lilly and Company - Phase II, 2016
  • Eli Lilly and Company - Phase I, 2016
  • Eli Lilly and Company - Preclinical, 2016
  • Eli Lilly and Company - Discovery, 2016
  • Eli Lilly and Company - Pipeline by Target, 2016
  • Eli Lilly and Company - Pipeline by Route of Administration, 2016
  • Eli Lilly and Company - Pipeline by Molecule Type, 2016
  • Eli Lilly and Company - Pipeline Products by Mechanism of Action, 2016
  • Eli Lilly and Company - Recent Pipeline Updates, 2016
  • Eli Lilly and Company - Dormant Developmental Projects,2016
  • Eli Lilly and Company - Discontinued Pipeline Products, 2016
  • Eli Lilly and Company, Subsidiaries
  • Eli Lilly and Company, Key Manufacturing Facilities

List of Figures

  • Eli Lilly and Company - Pipeline by Top 10 Indication, 2016
  • Eli Lilly and Company - Pipeline by Stage of Development, 2016
  • Eli Lilly and Company - Monotherapy Products in Pipeline, 2016
  • Eli Lilly and Company - Partnered Products in Pipeline, 2016
  • Eli Lilly and Company - Out-Licensed Products in Pipeline, 2016
  • Eli Lilly and Company - Pipeline by Top 10 Target, 2016
  • Eli Lilly and Company - Pipeline by Route of Administration, 2016
  • Eli Lilly and Company - Pipeline by Molecule Type, 2016
  • Eli Lilly and Company - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top